// App-Quantinova.ai

: Momelotinib (MMB) Long-Term Safety: Pooled Data from Three Phase 3 Randomized-Controlled Trials (RCTs)

Researchers

Presenter

  • Srdan Verstovsek

Principal Investigators

  • Vikas Gupta

  • David Lavie

  • Viviane Dubruille

  • Nathalie Cambier

  • Uwe Platzbecker

  • Marek Hus

  • Blanca Xicoy

  • Stephen T Oh

  • Jean-Jacques Kiladjian

  • Alessandro M Vannucchi

  • Aaron T. Gerds

  • Miklos Egyed

  • Jiri Mayer

  • Tomasz Sacha

  • Jun Kawashima

  • Marc Morris

  • Mei Huang

  • Claire Harrison

Medical Centers

  • UT Health San Antonio Cancer Center, San Antonio, TX

  • Guy's and St Thomas’ NHS Foundation Trust, London, United Kingdom

  • Jagiellonian University Hospital, Kraków, Poland

  • Universitat Autonoma de Barcelona, Barcelona, Spain

  • Department for Hematology, Cell Therapy and Hemostaseology, University of Leipzig Medical Center, Leipzig, Germany

  • Hadassah-Hebrew University Medical Centre, Jerusalem, Israel

  • Leukemia Department, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Division of Medical Oncology and Hematology, University Health Network, Toronto, Canada

  • Masaryk University and University Hospital Brno, Brno, Czech Republic

  • Hospital Saint Vincent de Paul-GHICL Lille, Lillie, France

  • University of Florence, Firenze, Italy

  • Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

  • Somogy County Mór Kaposi General Hospital, Kaposvár, Hungary

  • Hematology Department, Nantes University Hospital, Nantes, France

  • Université de Paris, AP-HP, Hôpital Saint-Louis, Centre d'Investigations Cliniques, Paris, France

  • Medical University of Lublin, Lublin, Poland

  • Siteman Cancer Center, Washington University School of Medicine, Saint Louis, MO

Locations

  • United States

  • France

  • Israel

  • United Kingdom

  • Italy

  • Poland

  • Canada

  • Spain

  • Hungary

  • Czech Republic

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Momelotinib

  • Ruxolitinib phosphate

  • Danazol

Outcome

  • N/A

Study Design

  • Randomized

  • Safety

  • Cross Over

  • Open Label

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved